Author:
Tahmasebi Safa,Elahi Reza,Esmaeilzadeh Abdolreza
Publisher
Springer Science and Business Media LLC
Reference150 articles.
1. Xia, A.-L., Wang, X.-C., Lu, Y.-J., Lu, X.-J., & Sun, B. (2017). Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities. Oncotarget., 8(52), 90521.
2. Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., et al. (2016). A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget., 7(19), 27764.
3. Elahi, R., Khosh, E., Tahmasebi, S., & Esmaeilzadeh, A. (2018). Immune cell hacking: Challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Frontiers in Immunology, 9.
https://doi.org/10.3389/fimmu.2018.01717
.
4. Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate Cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. The Prostate., 76(14), 1257–1270.
5. Romero, D. (2018). Haematological cancer: Favourable outcomes with CAR T cells. Nature Reviews. Clinical Oncology, 15(2), 65.
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献